Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.
作者信息
Taccone Fabio S, Gorham Julie, Vincent Jean-Louis
机构信息
Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium.
Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium.
出版信息
Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15.
Abstract
摘要
相似文献
1
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.羟氯喹在COVID-19危重症患者管理中的应用：循证依据的必要性。
Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15.
2
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.氯喹和羟氯喹的手性转换：治疗新冠肺炎的潜在药物
Drug Discov Today. 2020 Jul;25(7):1121-1123. doi: 10.1016/j.drudis.2020.04.021. Epub 2020 May 1.
3
Covid-19 treatment update: follow the scientific evidence.新冠病毒疾病治疗进展：遵循科学证据。
J Thromb Thrombolysis. 2020 Jul;50(1):43-53. doi: 10.1007/s11239-020-02120-9.
4
Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.揭示羟氯喹在新型冠状病毒肺炎中的证据
Crit Care. 2020 Apr 28;24(1):182. doi: 10.1186/s13054-020-02894-7.
5
Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.羟氯喹治疗新型冠状病毒肺炎：在等待确凿科学证据期间如何使用
Med Clin (Barc). 2020 Aug 14;155(3):134-135. doi: 10.1016/j.medcli.2020.05.006. Epub 2020 May 16.
6
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.在 COVID-19 大流行期间使用羟氯喹和氯喹：每个临床医生都应该知道的事。
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
7
Repurposing antimalarials and other drugs for COVID-19.将抗疟药及其他药物重新用于治疗新冠肺炎。
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
8
[Not Available].[不可用]。
Rev Med Suisse. 2020 Apr 15;16(690):756-757.
9
Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.用于治疗冠状病毒的羟氯喹：迫切需要暂停处方使用
Am J Med. 2020 Sep;133(9):1007-1008. doi: 10.1016/j.amjmed.2020.05.005. Epub 2020 Jun 2.
10
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Apr 8;16(689):704-705.
引用本文的文献
1
Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update.对抗新型冠状病毒肺炎的新兴治疗与预防策略：简要更新
J Dig Endosc. 2020 Mar;11(1):69-72. doi: 10.1055/s-0040-1712547. Epub 2020 May 16.
2
COVID-19 pandemic: A multifaceted challenge for science and healthcare.新冠疫情：对科学与医疗保健的多方面挑战。
Trends Anaesth Crit Care. 2020 Oct;34:1-3. doi: 10.1016/j.tacc.2020.08.009. Epub 2020 Sep 20.
3
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.基于蛋白质结构的计算机辅助药物发现方法：针对 COVID-19 治疗的指导。
Mol Aspects Med. 2023 Jun;91:101151. doi: 10.1016/j.mam.2022.101151. Epub 2022 Oct 28.
4
Knowledge and Compliance of Hydroxychloroquine Prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Indian Health-Care Workers.印度医护人员对羟氯喹预防严重急性呼吸综合征冠状病毒2感染的认知与依从性
J Res Pharm Pract. 2022 Aug 18;11(1):33-39. doi: 10.4103/jrpp.jrpp_50_21. eCollection 2022 Jan-Mar.
5
The prospects of employing probiotics in combating COVID-19.使用益生菌对抗新冠病毒的前景。
Tzu Chi Med J. 2021 Oct 5;34(2):148-159. doi: 10.4103/tcmj.tcmj_104_21. eCollection 2022 Apr-Jun.
6
Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.锌增强了羟氯喹/氯喹和伊维菌素的抗病毒潜力，降低了 COVID-19 感染导致更严重后果的风险。
J Trace Elem Med Biol. 2022 May;71:126954. doi: 10.1016/j.jtemb.2022.126954. Epub 2022 Feb 17.
7
Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.血心屏障渗漏机制：对 COVID-19 引起的心血管损伤的影响。
Int J Mol Sci. 2021 Dec 17;22(24):13546. doi: 10.3390/ijms222413546.
8
Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19.羟氯喹治疗 COVID-19 时可能存在的有临床意义的药物相互作用。
Int J Clin Pract. 2021 Nov;75(11):e14710. doi: 10.1111/ijcp.14710. Epub 2021 Aug 16.
9
The Impact of Media on Public Health Awareness Concerning the Use of Natural Remedies Against the COVID-19 Outbreak in Saudi Arabia.媒体对沙特阿拉伯公众关于使用天然药物对抗新冠疫情的健康意识的影响。
Int J Gen Med. 2021 Jul 2;14:3145-3152. doi: 10.2147/IJGM.S317348. eCollection 2021.
10
Electron Donor-Acceptor Capacity of Selected Pharmaceuticals against COVID-19.部分药物对新型冠状病毒的电子供体-受体能力
Antioxidants (Basel). 2021 Jun 18;10(6):979. doi: 10.3390/antiox10060979.
本文引用的文献
1
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
2
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.羟氯喹和阿奇霉素联合治疗至少随访 6 天的 80 例 COVID-19 患者的临床和微生物学效果：一项前瞻性观察研究。
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
3
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
4
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).拯救脓毒症运动：2019 冠状病毒病（COVID-19）危重症成人管理指南。
Intensive Care Med. 2020 May;46(5):854-887. doi: 10.1007/s00134-020-06022-5. Epub 2020 Mar 28.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
7
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.一项关于氯喹治疗 COVID-19 的疗效和安全性的系统评价。
J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.
8
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
9
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
10
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
Zotero 插件